SOMERSET HOSPITAL
1. Target Overview & Investment Thesis
SOMERSET HOSPITAL is a 56-bed suburban community hospital in SOMERSET, PA with $82.5M in net patient revenue and a -3.1% operating margin. The hospital serves a payer mix of 15.7% Medicare, 6.2% Medicaid, and 78.1% commercial.
Thesis: Turnaround. Our ML models identify $6.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -3.1% to 4.3% (+736bps).
| Net Revenue HCRIS | $82.5M |
| Current EBITDA COMPUTED | $-2.5M |
| Operating Margin COMPUTED | -3.1% |
| Occupancy HCRIS | 59.3% |
| Revenue / Bed COMPUTED | $1.5M |
| Net-to-Gross HCRIS | 25.8% |
| Distress Probability ML | 45.0% |
2. Market Context & Competitive Position
PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -3.1% places it above the state median. Among 85 size-comparable peers (28-112 beds), the median margin is 0.4%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (28-112), prioritizing same-state peers. 85 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| SOMERSET HOSPITAL (Target) | PA | 56 | $82.5M | -3.1% |
| THE GETTYSBURG HOSPITAL | PA | 76 | $341.8M | 18.4% |
| AMERICAN ONCOLOGIC HOSPIAL | PA | 100 | $229.8M | -11.1% |
| ST. LUKES HOSPITAL - MONROE CA | PA | 98 | $221.8M | 7.8% |
| GEISINGER LEWISTOWN HOSPITAL | PA | 107 | $210.8M | 11.2% |
| UPMC HANOVER | PA | 73 | $200.8M | 18.2% |
| MEMORIAL HOSPITAL | PA | 80 | $184.5M | 13.1% |
| UPMC CARLISLE | PA | 72 | $165.0M | 19.5% |
| UPMC HORIZON HOSPITAL | PA | 99 | $156.4M | -16.5% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $6.1M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $1.7M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $1.7M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $1.6M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $1.0M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $53K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-2.5M |
| + RCM Uplift | +$6.1M |
| Pro Forma EBITDA | $3.6M |
| Current Margin | -3.1% |
| Pro Forma Margin | 4.3% |
| WC Released (1x) | $3.2M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-3.9M | $44.1M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-3.9M | $47.3M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-3.5M | $66.1M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-3.5M | $71.0M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-4.3M | $15.0M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-4.3M | $15.1M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 85 hospitals with 28-112 beds
- Same-state prioritization (n=86)
- Comp margins: P25=-18.2% / P50=0.4% / P75=9.1%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.